A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small lung cancer (NSCLC)

被引：0
|
作者：
Camidge, D. R.
Ballas, M. S.
Dubey, S.
Haigentz, M.
Rosen, P. J.
Spicer, J. F.
West, H. J.
Shah, G. D.
Youssoufian, H.
Mita, A. C.
机构：
[1] Univ Colorado Denver, Aurora, CO USA
[2] NYU, Ctr Canc, New York, NY USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Montefiore Med Ctr, Bronx, NY 10467 USA
[5] Tower Canc Res Fdn, Beverly Hills, CA USA
[6] Guys Hosp, Div Canc Studies, Kings Coll London, London SE1 9RT, England
[7] Swedish Canc Inst, Seattle, WA USA
[8] ImClone Syst, New York, NY USA
[9] ImClone Syst, Branchburg, NJ USA
[10] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FINAL RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF RAMUCIRUMAB (IMC-1121B; RAM), AN IGG1 MAB TARGETING VEGFR-2, WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) (NCT00735696)
    Camidge, D. R.
    Doebele, R. C.
    Ballas, M.
    Jahan, T.
    Haigentz, M.
    Hoffman, D.
    Spicer, J.
    West, H.
    Yurasov, S.
    Mita, A. C.
    ANNALS OF ONCOLOGY, 2012, 23 : 422 - 423
  • [2] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
  • [3] A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors
    Spratlin, Jennifer L.
    Eckhardt, S. Gail
    Gore, Lia
    Camidge, D. Ross
    Leong, Stephen
    O'Bryant, Cindy
    Diab, Sami
    Chow, Laura Q. M.
    Youssoufian, Hagop
    Fox, Floyd
    Cohen, Roger B.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3346S - 3346S
  • [4] A PHASE II STUDY OF FIRST-LINE BORTEZOMIB (B) IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC)
    Planchard, D.
    Besse, B.
    Meric, J. B.
    Veillard, A. S.
    Pignon, J. P.
    Chan, K.
    Mathiot, C.
    Lumbroso, J.
    Lafontaine, C.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 96 - 96
  • [5] PHASE II RANDOMIZED, OPEN-LABEL STUDY OF CETUXIMAB (CET) AND BEVACIZUMAB (BEV) IN COMBINATION WITH PACLITAXEL (P) AND CARBOPLATIN (C) IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Bonomi, Philip
    Mace, Joseph
    Mandana, Romeo
    Min, Myo
    Mark, Olsen
    Youssoufian, Hagop
    Katz, Terry
    Simms, Lorinda
    Lee, Hyun Jung
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1292 - S1292
  • [6] Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
    Lynch, T. J.
    Bondarenko, I. N.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R. T.
    Sebastian, M.
    Siegel, J.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer.
    Camidge, D. R.
    Eckhardt, S. G.
    Diab, S.
    Gore, L.
    Chow, L.
    O'Bryant, C.
    Temmer, E.
    Ervin-Haynes, A.
    Katz, T.
    Fox, F.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 128S - 128S
  • [8] DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: Report of a phase II open-label multicenter trial
    Payne, Miranda
    Ellis, Paul
    Dunlop, David
    Ranson, Malcolm
    Danson, Sarah
    Schacter, Lee
    Talbot, Denis
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 984 - 990
  • [9] A PHASE 2 RANDOMIZED OPEN-LABEL STUDY OF RAMUCIRUMAB (IMC 1121B; RAM) IN COMBINATION WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS (PTS) WITH RECURRENT OR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RESULTS FROM NON-SQUAMOUS (NSQ) PTS (NCT01160744)
    Doebele, Robert C.
    Spigel, David
    Tehfe, Mustapha
    Thomas, Sachdev
    Reck, Martin
    Verma, Sunil
    Yurasov, Sergey
    Camidge, David Ross
    Bonomi, Philip
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S290 - S290
  • [10] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    CANCER RESEARCH, 2012, 72
12345